# Zhenya Tang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6262097/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 41 papers | 573 citations | 687363 13 h-index | 677142 22 g-index |
| 42 all docs | 42 docs citations | 42 times ranked | 890 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies. Cancer Genetics, 2022, 262-263, 23-29. | 0.4 | 2 |
| 2 | 3â€²CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant. Annals of Hematology, 2022, 101, 847-854. | 1.8 | 2 |
| 3 | TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood, 2022, 140, 58-72. | 1.4 | 46 |
| 4 | MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome. Cancers, 2022, 14, 2433. | 3.7 | 7 |
| 5 | Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. Pathology, 2022, , . | 0.6 | 0 |
| 6 | Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2022, 14, 3375. | 3.7 | 8 |
| 7 | MET Amplification (MET/CEP7 RatioÂ‰¥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Nonâ€“Small-cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e512-e518. | 2.6 | 10 |
| 8 | Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome. Experimental and Molecular Pathology, 2021, 118, 104572. | 2.1 | 3 |
| 9 | Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. Modern Pathology, 2021, 34, 300-313. | 5.5 | 6 |
| 10 | Clinicopathologic Features of Myelodysplastic Syndromes Involving Lymph Nodes. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 930-938. | 3.7 | 0 |
| 11 | Incidental identification of inv(16)(p13.1q22)/CBFBâ€“MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. Journal of Physical Education and Sports Management, 2021, 7, a006084. | 1.2 | 3 |
| 12 | Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer Journal, 2021, 11, 162. | 6.2 | 32 |
| 13 | CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. Cancers, 2021, 13, 5354. | 3.7 | 3 |
| 14 | Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2021, 13, 5888. | 3.7 | 15 |
| 15 | Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors. Cancer Genetics, 2020, 241, 57-60. | 0.4 | 4 |
| 16 | Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes. Cancers, 2020, 12, 1903. | 3.7 | 0 |
| 17 | Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement. Leukemia Research, 2020, 99, 106460. | 0.8 | 14 |
| 18 | Chronic myeloid leukemia with insertion-derived BCRâ€“ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis. Modern Pathology, 2020, 33, 2035-2045. | 5.5 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | iAMP21 in acute myeloid leukemia is associated with complex karyotype, TP53 mutation and dismal outcome. Modern Pathology, 2020, 33, 1389-1397. | 5.5 | 8 |
| 20 | T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid. Leukemia, 2020, 34, 2509-2512. | 7.2 | 14 |
| 21 | Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer, 2020, 20, 83. | 2.6 | 10 |
| 22 | Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects. International Journal of Molecular Sciences, 2019, 20, 3939. | 4.1 | 27 |
| 23 | 7. Additional structural chromosomal abnormalities have a negative prognostic effect in patients with inv(16)/t(16;16) acute myeloid leukemia (AML). Cancer Genetics, 2019, 233-234, S3-S4. | 0.4 | 1 |
| 24 | Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Cancer Genetics, 2019, 238, 18-22. | 0.4 | 10 |
| 25 | 51. Clonal size of ALK rearrangements detected by FISH is associated with the duration of progression free survival in metastatic lung cancer treated with ALK inhibitors. Cancer Genetics, 2019, 233-234, S20. | 0.4 | 1 |
| 26 | Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens. Leukemia Research, 2019, 84, 106176. | 0.8 | 7 |
| 27 | Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies. Data in Brief, 2019, 24, 104025. | 1.0 | 3 |
| 28 | PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2019, 11, 695. | 3.7 | 12 |
| 29 | Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. Cancer Genetics, 2019, 233-234, 21-31. | 0.4 | 13 |
| 30 | Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. American Journal of Surgical Pathology, 2019, 43, 1429-1437. | 3.7 | 59 |
| 31 | Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica, 2019, 104, 305-311. | 3.5 | 56 |
| 32 | t(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression. Journal of Molecular Diagnostics, 2019, 21, 343-351. | 2.8 | 16 |
| 33 | 3q26/ EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. Leukemia Research, 2018, 65, 25-28. | 0.8 | 6 |
| 34 | Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. Modern Pathology, 2018, 31, 307-312. | 5.5 | 24 |
| 35 | Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. Leukemia Research, 2018, 73, 86-94. | 0.8 | 29 |
| 36 | Quality Assurance/Quality Control of Fluorescence in Situ Hybridization Tests in Hematologic Malignancies. OBM Genetics, 2018, 2, 1-1. | 0.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Characterization of <scp>TP</scp>53 mutations in lowâ€grade myelodysplastic syndromes and myelodysplastic syndromes with a nonâ€complex karyotype. European Journal of Haematology, 2017, 99, 536-543. | 2.2 | 20 |
| 38 | P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Modern Pathology, 2017, 30, 194-203. | 5.5 | 72 |
| 39 | Simultaneous deletion of 3â€²ETV6 and 5â€²EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review. Molecular Cytogenetics, 2016, 9, 23. | 0.9 | 21 |
| 40 | Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Molecular Cytogenetics, 2015, 8, 68. | 0.9 | 5 |
| 41 | Myeloid neoplasms with 8q24/ <scp> MYC </scp> rearrangement are frequently associated with myelodysplasia, complex karyotype, <scp> TP53 </scp> alterations, and inferior survival. British Journal of Haematology, 0, , . | 2.5 | 0 |